Autoimmune Diseases  >>  Nucala (mepolizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nucala (mepolizumab) / GSK
MEPOCHUSS, NCT00716651 / 2006-001791-20: Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome

Completed
2
10
Europe
mepolizumab
University Hospital Schleswig-Holstein, GlaxoSmithKline
Churg Strauss Syndrome
07/10
 
NCT01705795: Anti-IL-5 Therapy in Bullous Pemphigoid (BP)

Completed
2
32
Europe
Mepolizumab (a-IL-5 antibody), Placebo
University Hospital Inselspital, Berne
Pemphigoid, Bullous
01/17
01/17
MATOCSS, NCT00527566: Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome

Completed
1/2
10
US
Mepolizumab, Anti IL-5
Brigham and Women's Hospital, GlaxoSmithKline
Churg Strauss Syndrome
08/09
08/09

Download Options